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Background
Treatment with anti-TNF (tumor necrosis factor) agents
has been effective in many inflammatory conditions.
However, severe adverse events can occur, even after
years of therapy. Damage of central nervous system has
been well documented in adults.
Aim
To draw attention to the possibility of neurological
complications of anti-TNF therapy in children.
Methods
Clinical and radiological discussion of a 13 yr. old boy
who presented to our Emergency Unit due to the
impossibility for standing up or walking in the last 24
hours. During the previous days he had noticed some
paresthesias in the lower extremities and difficulty initi-
ating urination and defecation. Physical examination
revealed normal muscle tone and tendon reflexes in his
upper extremities, but severely diminished muscle
strength in the lower limbs, hyperreflexia and exhausti-
ble clonus. Cranial and spinal cord MRI performed the
same day revealed the existence of two lesions, one at
the cervical level (C2-C4) and another at the medullary
cone (T12-L1), showing enhancement after contrast
media administration. Diagnosis of demyelinating dis-
ease was performed. Treatment with etanercept had
been started eight years before together with methotrex-
ate due to the existence of inflammatory polyarthritis
(Blau syndrome).
Results
Etanercept was discontinued and the patient treated
with high-dose intravenous corticosteroids during five
days, followed by oral prednisone for six weeks. Func-
tional recovery was achieved after four weeks.
Conclusion
Central nervous system damage related with TNF block-
ade could appear also in children, even in those patients
who did not present any side effect for prolonged peri-
ods of time.
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